What I Do
Product & Portfolio Governance
Your product org ships late, kills too slow, and can't tell you which products are worth the investment. I created FORGE — a complete product lifecycle framework with seven phases, kill criteria, and a dual-lane architecture that separates exploration from execution. I'll implement it in your org so products move on a clock, not a prayer.
24 templates. 7 phases. Implemented inside a national payer's product organization.
VBC & Specialty Risk Strategy
You're negotiating value-based contracts and the model lives in a spreadsheet one person understands. I'll model the contract, stress-test the corridors, and give you a financial picture you can defend in the room. I built Cadence, Curated, Caliber, and Compass from this exact work.
ClearBill, my billing-integrity platform, returned $9.2M to payers in its first six months of full deployment. 65,234 patients studied across three cohorts.
Organizational Architecture
Your org just swung too far toward control and the builders are leaving. Or too far toward speed and nothing is governed. I've spent a decade and a half in that cycle. I'll design the structure that holds both — PE portfolio companies, post-M&A integration, product org redesign.
200,000+ patients across the companies I've led. Built from scratch. Ran as CEO through acquisition.
I also design clinical programs, build financial models, conduct market research, and develop intellectual property. If you need someone who operates across the full stack — strategy through shipped product — that's the engagement.
Most recent: Staff Vice President, Specialty Risk Product Strategy, Carelon Growth (Elevance Health). Redesigned the specialty risk commercialization process for the health services subsidiary. Single author. Now the operating standard across the organization. · Previous: Benefits strategy advisory for a Fortune 100 retailer's benefits organization.
How It Works
- Monthly retainer. Not hourly. Not project-based. You get a product leader, not a consultant.
- What you get: product strategy, financial models, governance frameworks, market research, competitive positioning — delivered, not recommended.
- Published tiers: $10,000/mo (monthly governance assessment + 4 hours direct advisory) · $20,000/mo (strategy document + weekly working sessions + deliverable review) · $35,000/mo (embedded in your org, operating rhythm, shipping alongside your team) · $50,000+/mo (full fractional CPO with P&L-level ownership). Scope defines the tier, not hours.
- Engagements are capped to preserve depth. You get the person who built the methodology, not someone who read the slide deck.
- Direct access. No associates, no junior team, no handoff.
- Minimum 3-month engagement. Most stay longer.
The Right Fit
The best engagements start with a real problem. Sometimes you know exactly what's broken. Sometimes you need someone to find it. I do both — diagnose the gap, design the fix, and ship it. Discovery, strategy, architecture, execution. Same rigor at every stage.
Who This Is For
- Health plans managing specialty risk books that need product strategy, governance design, VBC modeling, and a PLM framework that actually ships.
- Health systems entering value-based contracts — I model the math, design the clinical programs, and build the operating infrastructure from scratch.
- Provider organizations scaling operations — site scouting, provider recruitment, telehealth program design, and service line buildout across BH, SUD, maternity, and primary care.
- PE firms with healthcare portfolio companies that need an operator for M&A due diligence, post-acquisition integration, and unit economics that hold up under scrutiny.
- Digital health companies that need a fractional CPO who's been on the payer side deciding what to buy — product leadership, regulatory navigation, and procurement survival.
- Self-funded employers and brokers who need governance over specialty pharmacy and behavioral health spend — stop-loss strategy, renewal positioning, and clinical accountability.
- Organizations building data strategy from research-grade evidence — 65,234 patients studied, published in Pharmacy Times, NIH-validated methodology.